Kabonk,

Thanks for that article.
Undoubtedly more than one pathology contributes to ALS. I hope that, with the common pathway of secondary neuroinflammation, irrespective of initial insult or mutation, that Leronlimab may slow disease progression.

Here is a good review describing the range of pathologies involved in ALS, including the astrocyte toxicity as you noted.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567007/

Role of Neuroinflammation in Amyotrophic Lateral Sclerosis: Cellular Mechanisms and Therapeutic Implications

Abstract states in part:

Quote:

---

Increasing evidence indicates that neuroinflammation plays an important role in ALS pathogenesis. The neuroinflammation in ALS is characterized by infiltration of lymphocytes and macrophages, activation of microglia and reactive astrocytes, as well as the involvement of complement. In this review, we focus on the key cellular players of neuroinflammation during the pathogenesis of ALS by discussing not only their detrimental roles but also their immunomodulatory actions

---